Progress in therapeutic targets on podocyte for Alport syndrome

被引：0
作者：
Zheng, Qimin [1 ,2 ]
Gu, Xiangchen [1 ,2 ]
He, John Cijiang [3 ]
Xie, Jingyuan [1 ,2 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Sch Med, Dept Nephrol, Shanghai 200025, Peoples R China
[2] Shanghai Jiao Tong Univ, Inst Nephrol, Sch Med, Shanghai, Peoples R China
[3] Icahn Sch Med Mt Sinai, Dept Med, Barbara T Murphy Div Nephrol, New York, NY USA
来源：
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE | 2024年 / 12卷 / 02期
基金：
中国国家自然科学基金;
关键词：
Alport syndrome; podocyte; therapeutic targets; UNFOLDED PROTEIN RESPONSE; IV COLLAGEN; CELL-CYCLE; DISEASE PROGRESSION; MUTATIONS; GLOMERULI; AUTOPHAGY; FIBROSIS; STRESS;
D O I：
10.2478/jtim-2024-0005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：129 / 133
页数：5
相关论文
共 50 条
  • [1] Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome
    Ding, Fangrui
    Wickman, Larysa
    Wang, Su Q.
    Zhang, Yanqin
    Wang, Fang
    Afshinnia, Farsad
    Hodgin, Jeffrey
    Ding, Jie
    Wiggins, Roger C.
    KIDNEY INTERNATIONAL, 2017, 92 (06) : 1515 - 1525
  • [2] Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
    Ge, Mengyuan
    Molina, Judith
    Kim, Jin-Ju
    Mallela, Shamroop K.
    Ahmad, Anis
    Varona Santos, Javier
    Al-Ali, Hassan
    Mitrofanova, Alla
    Sharma, Kumar
    Fontanesi, Flavia
    Merscher, Sandra
    Fornoni, Alessia
    ELIFE, 2023, 12
  • [3] Podocyte Depletion in Thin GBM and Alport Syndrome
    Wickman, Larysa
    Hodgin, Jeffrey B.
    Wang, Su Q.
    Afshinnia, Farsad
    Kershaw, David
    Wiggins, Roger C.
    PLOS ONE, 2016, 11 (05):
  • [4] Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome
    Kim, Jin-Ju
    David, Judith M.
    Wilbon, Sydney S.
    Santos, Javier, V
    Patel, Devang M.
    Ahmad, Anis
    Mitrofanova, Alla
    Liu, Xiaochen
    Mallela, Shamroop K.
    Ducasa, Gloria M.
    Ge, Mengyuan
    Sloan, Alexis J.
    Al-Ali, Hassan
    Boulina, Marcia
    Mendez, Armando J.
    Contreras, Gabriel N.
    Prunotto, Marco
    Sohail, Anjum
    Fridman, Rafael
    Miner, Jeffrey H.
    Merscher, Sandra
    Fornoni, Alessia
    EBIOMEDICINE, 2021, 63
  • [5] Alport Syndrome: Clinical Spectrum and Therapeutic Advances
    De Gregorio, Vanessa
    Caparali, Emine Bilge
    Shojaei, Azadeh
    Ricardo, Samantha
    Barua, Moumita
    KIDNEY MEDICINE, 2023, 5 (05)
  • [6] Effect of disease progression on the podocyte cell cycle in Alport Syndrome
    Frank, Camille Nicolas
    Hou, Xiaogang
    Petrosyan, Astgik
    Villani, Valentina
    Zhao, Rui
    Hansen, Joshua R.
    Clair, Geremy
    Salem, Fadi
    De Filippo, Roger E.
    Cravedi, Paolo
    Lemley, Kevin, V
    Perin, Laura
    KIDNEY INTERNATIONAL, 2022, 101 (01) : 106 - 118
  • [7] Podocyte p53 Limits the Severity of Experimental Alport Syndrome
    Fukuda, Ryosuke
    Suico, Mary Ann
    Kai, Yukari
    Omachi, Kohei
    Motomura, Keishi
    Koga, Tomoaki
    Komohara, Yoshihiro
    Koyama, Kosuke
    Yokota, Tsubasa
    Taura, Manabu
    Shuto, Tsuyoshi
    Kai, Hirofumi
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (01): : 144 - 157
  • [8] Could This Be Alport Syndrome?
    Lennon, Rachel
    Fornoni, Alessia
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (11): : 1743 - 1745
  • [9] New therapeutic options for Alport syndrome
    Torra, Roser
    Furlano, Monica
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (08) : 1272 - 1279
  • [10] Alport syndrome and Alport kidney diseases - elucidating the disease spectrum
    Puapatanakul, Pongpratch
    Miner, Jeffrey H.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2024, 33 (03) : 283 - 290
12345